Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 366 participants.

Also called NCT03469349

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 366 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03469349
  • EudraCT 2017-004741-24
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Georgia, Kazakhstan, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03469349. Randomized; double masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2019-05-28 (actual). Results posted on 2020-10-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
Acronym
APOLLO
Condition
Peripheral Arterial Diseases
Intervention (Drug)
Actovegin
Intervention (Drug)
Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct03469349
Content hash
5e9e3a425b4eda5357935ee0c584d8d37bdf5e2e8abdad2215f54bdbc2e76039